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In the past 10 years, research on autism spectrum disorders (ASD)
has made a considerable progress, leading to the identification
of a number of genes and signaling pathways associated to ASD
pathogenesis. Nevertheless, our understanding of the complexity
of these disorders remains elusive, and effective treatments are
still lacking (1). In this e-book, we present 16 articles address-
ing several different aspects of both clinical and basic research on
ASD. A particular emphasis is put on the efforts that are currently
made to identify reliable diagnostic markers and novel therapeutic
strategies, as well as on the progress of ongoing clinical trials.
Though ASD are recognized as cross-cultural disorders, dis-
crepancies in early diagnosis and interventions are present in west-
ern countries. Genetic testing procedures in Europe and USA are
still discordant; these issues are addressed by Amiet and coworkers
(2). New ASD treatments are emerging and deserve to be men-
tioned. A number of novel medications have been used off-label
in various studies, including drugs approved for Alzheimer’s dis-
ease, as reviewed by Rossignol and Frye (3). Among these, it has
to be outlined that in a large multisite controlled study meman-
tine was not shown to improve core and associated symptoms
in ASD and the open phase of the trial was in fact suspended.
Similarly, cholinesterase inhibitors did not show substantial modi-
fications in ASD core symptoms and their use is still not warranted.
Drugs commonly used to treat mitochondrial diseases such as L-
carnitine, complex B vitamins, antioxidants etc. have been found
to improve ASD symptoms in some studies,but results are still con-
flicting and more research is needed. As a whole, the field is active
and in progress but reports are discordant and do not yet allow
us to draw firm conclusions regarding safety and efficacy. Further,
research is needed to define subgroups of children with ASD in
which these treatments may be most effective (4). ASD children
treated with a ketogenic diet (KGD) showed decreased seizure
frequencies and improved learning abilities and social skills, as
proposed by Napoli and coworkers (5); however, replications of
this investigation are urgently awaited to have of a clearer picture
of KGD role in ASD. Excitation and inhibition (E/I) imbalance in
ASD has been demonstrated in preclinical models, and targeted
treatments directed either to reduce excessive glutamatergic trans-
mission or increase inhibition through stimulation of GABAer-
gic signaling have been introduced with promising preliminary
results. The implication of oxytocin in social development and
affiliative behaviors has been ascertained and findings from clinical
trials in children with ASD showed encouraging results espe-
cially in social cognition. Stimulation of excitatory synapses and
neuronal density has been achieved with insulin-like growth fac-
tor 1 (IGF-1) administration and it has been positively tested in
two single gene disorders associated with ASD, Rett syndrome,
and Phelan-McDermid syndrome. These preliminary clinical trials
point to additional research in larger samples. Notably, modi-
fications of neural pathways of ASD have been observed after
behavioral developmental interventions through the evaluation by
functional neuroimaging and electroencephalography, providing
evidence of a dynamic neural substrate susceptible of functional
changes. This new conceptualization paves the way to a modern
treatment approach to this group of disorders once thought as
hard wired and not amenable of changing, as discussed in the
papers by Pini and colleagues (6) and Canitano (7).
The role of melatonin in the establishment of circadian rhythms
and the synchronization of peripheral oscillators is probably linked
to the synchrony of motor, emotional, and social rhythms that
are altered in ASD. Potential therapeutic benefits of melatonin
in the recovery of circadian rhythms have been demonstrated in
a growing number of studies in ASD. Developmental behavioral
interventions that emphasize synchrony (in some cases combined
with melatonin) seem to provide substantial improvement in
ASD, as reviewed by Tordjman (8) and reported by Fulton (9).
Research on outcome of interventions is currently an active field
of investigation, though data available do not allow to answer the
question of “what works for whom” in ASD. This is critical to
delineate the guidelines for behavioral interventions, as reviewed
byVivanti and colleagues (10). Among the bothersome ASD symp-
toms that need to be addressed, auditory hypersensitivities may be
tackled by means of novel techniques such as the listening pro-
tocol projects, as proposed by Porges (11). Poor reciprocal social
communication is a hallmark characteristic of ASD and is under
intense investigation for treatment; Corbett and colleagues report
a novel theatre intervention that combines interaction of trained
peers with patients to facilitate the performance-based theatrical
treatment (12).
The last part of the book is dedicated to basic studies highlight-
ing the importance of investigating mouse models to unravel the
molecular mechanisms underlying ASD pathogenesis. Two review
articles, respectively by Cellot and Cherubini (13) and Giovedí
and coworkers (14), address the role of GABAergic neurotrans-
mission and synaptic vesicle proteins in the pathogenesis of ASD,
strengthening the notion of ASD as a “synaptic neuropathology”.
Finally, three original research articles investigate novel pathologi-
cal aspects in three different ASD mouse models. Provenzano and
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colleagues show growth hormone and IGF-1 signaling deficits in
Engrailed-2 mouse mutants (15); Gigliucci et al. demonstrate oxy-
tocin signaling alterations in mice lacking opioid receptors (16),
and Michetti and coworkers identify a series of pathological fea-
tures (including defects in glutamatergic neurotransmission) in
reeler mice (17). Taken together, these mouse studies confirm the
importance of IGF-1, oxytocin, and glutamate signaling in the
pathogenesis of ASD, as extensively described in several clinical
studies presented in this e-book.
REFERENCES
1. Ecker C, Spooren W, Murphy DG. Translational approaches to the biology
of autism: false dawn or a new era? Mol Psychiatry (2013) 18(4):435–42.
doi:10.1038/mp.2012.102
2. Amiet C, Couchon E, Carr K, Carayol J, Cohen D. Are there cultural differences
in parental interest in early diagnosis and genetic risk assessment for autism
spectrum disorder? Front Pediatr (2014) 2:32. doi:10.3389/fped.2014.00032
3. Rossignol DA, Frye RE. The use of medications approved for Alzheimer’s dis-
ease in autism spectrum disorder: a systematic review. Front Pediatr (2014) 2:87.
doi:10.3389/fped.2014.00087
4. Frye RE, Rossignol DA. Treatments for biomedical abnormalities associated
with autism spectrum disorder. Front Pediatr (2014) 2:66. doi:10.3389/fped.
2014.00066
5. Napoli E, Dueñas N, Giulivi C. Potential therapeutic use of the ketogenic diet in
autism spectrum disorders. Front Pediatr (2014) 2:69. doi:10.3389/fped.2014.
00069
6. Pini G, Scusa MF, Benincasa A, Bottiglioni I, Congiu L, Vadhatpour C, et al.
Repeated insulin-like growth factor 1 treatment in a patient with rett syndrome:
a single case study. Front Pediatr (2014) 2:52. doi:10.3389/fped.2014.00052
7. Canitano R. New experimental treatments for core social domain in autism
spectrum disorders. Front Pediatr (2014) 2:61. doi:10.3389/fped.2014.00061
8. Tordjman S, Davlantis K, Georgieff N, Speranza M, Xavier J, Botbol M, et al.
Autism as a disorder of biological and behavioral rhythms: towards new thera-
peutic perspectives. Front Pediatr (2015) 3:1. doi:10.3389/fped.2015.00001
9. Fulton E, Eapen V, Crncˇec R, Walter A, Rogers S. Reducing maladaptive
behaviors in preschool aged children with autism spectrum disorder using
the early start denver model. Front Pediatr (2014) 2:40. doi:10.3389/fped.2014.
00040
10. Vivanti G, Prior M, Williams K, Dissanayake C. Predictors of outcomes in
autism early intervention: why don’t we know more? Front Pediatr (2014) 2:58.
doi:10.3389/fped.2014.00058
11. Porges SW, Bazhenova OV, Bal E, Carlson N, Sorokin Y, Heilman KJ, et al.
Reducing auditory hypersensitivities in autistic spectrum disorder: preliminary
findings evaluating the listening project protocol. Front Pediatr (2014) 2:80.
doi:10.3389/fped.2014.00080
12. Corbett BA, Qualls LR, Valencia B, Fecteau SM, Swain DM. Peer-mediated the-
atrical engagement for improving reciprocal social interaction in autism spec-
trum disorder. Front Pediatr (2014) 2:110. doi:10.3389/fped.2014.00110
13. Cellot G, Cherubini E. GABAergic signaling as therapeutic target for autism-
spectrum disorders. Front Pediatr (2014) 2:70. doi:10.3389/fped.2014.00070
14. Giovedí S, Corradi A, Fassio A, Benfenati F. Involvement of synaptic genes in the
pathogenesis of autism spectrum disorders: the case of synapsins. Front Pediatr
(2014) 2:94. doi:10.3389/fped.2014.00094
15. Provenzano G, Clementi E, Genovesi S, Scali M, Tripathi PP, Sgadò P, et al. GH
dysfunction in engrailed-2 knockout mice, a model for autism spectrum disor-
ders. Front Pediatr (2014) 2:92. doi:10.3389/fped.2014.00092
16. Gigliucci V, Leonzino M, Busnelli M, Luchetti A, Palladino VS, D’Amato FR, et al.
Region specific up-regulation of oxytocin receptors in the opioid oprm1 (-/-)
mouse model of autism. Front Pediatr (2014) 2:91. doi:10.3389/fped.2014.00091
17. Michetti C, Romano E, Altabella L, Caruso A, Castelluccio P, Bedse G, et al.
Mapping pathological phenotypes in reelinmutant mice. Front Pediatr (2014)
2:95. doi:10.3389/fped.2014.00095
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 22 January 2015; accepted: 06March 2015; published online: 18March 2015.
Citation: Canitano R and Bozzi Y (2015) New treatment perspectives in autism
spectrum disorders. Front. Pediatr. 3:22. doi: 10.3389/fped.2015.00022
This article was submitted to Child and Neurodevelopmental Psychiatry, a section of
the journal Frontiers in Pediatrics.
Copyright © 2015 Canitano and Bozzi. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Pediatrics | Child and Neurodevelopmental Psychiatry March 2015 | Volume 3 | Article 22 | 2
